RAPT Therapeutics Inc [RAPT] stock prices are up 43.34% to $1.23 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RAPT shares have gain 46.69% over the last week, with a monthly amount glided 40.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on December 26, 2024, and kept the price target unchanged to $10. On November 13, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on November 11, 2024. JP Morgan downgraded its rating to a Underweight. Wolfe Research downgraded its rating to Peer Perform for this stock on May 14, 2024. In a note dated May 10, 2024, Guggenheim downgraded an Neutral rating on this stock.
The stock price of RAPT Therapeutics Inc [RAPT] has been fluctuating between $0.71 and $4.74 over the past year. Currently, Wall Street analysts expect the stock to reach $30.71 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $1.23 at the most recent close of the market. An investor can expect a potential return of 2396.75% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -0.81 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9659 points at the first support level, and at 0.7019 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3645, and for the 2nd resistance point, it is at 1.4991.
Ratios To Look Out For
It’s worth pointing out that RAPT Therapeutics Inc [NASDAQ:RAPT]’s Current Ratio is 21.11. In addition, the Quick Ratio stands at 21.11 and the Cash Ratio stands at 6.94.
